| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
AChE[1]
Acacetin-7-O-β-D-galactopyranoside targets acetylcholinesterase (AChE), acting as an inhibitor. It can be used for research of Alzheimer's disease. Its flavonoid structure also suggests potential antioxidant and anti-inflammatory activities, though these are not its primary targets in the context of AD research. |
|---|---|
| ln Vitro |
In cell-free enzyme assays, Acacetin-7-O-β-D-galactopyranoside inhibits AChE activity. These assays confirm its potential as a cholinesterase inhibitor for Alzheimer's disease research. Its inhibitory potency can be measured using standard AChE inhibition assays with chromogenic substrates. Cellular assays for Acacetin-7-O-β-D-galactopyranoside are not extensively detailed. However, as an AChE inhibitor, it would be expected to increase acetylcholine levels in neuronal cell cultures. Its neuroprotective effects could be assessed in models of neurodegeneration.
|
| ln Vivo |
In vivo, Acacetin-7-O-β-D-galactopyranoside has the potential for Alzheimer's disease research. It is a flavonoid extracted from Chrysanthemum morifolium. Studies on its specific in vivo effects are limited, but it is used in research on AD.
|
| Enzyme Assay |
Cell-free enzyme inhibition assays for Acacetin-7-O-β-D-galactopyranoside are performed using purified AChE enzyme. The enzyme is incubated with varying concentrations of the compound and a chromogenic substrate. The rate of substrate hydrolysis is measured spectrophotometrically, and the IC50 value is determined from the inhibition curve.
|
| Cell Assay |
Cellular assays for Acacetin-7-O-β-D-galactopyranoside could be conducted using neuronal cell lines. Cells would be treated with the compound, and markers of cholinergic function, such as acetylcholine levels, could be measured. Neuroprotective effects could be assessed in models of neurodegeneration.
|
| Animal Protocol |
In vivo studies on Acacetin-7-O-β-D-galactopyranoside are not extensively reported. For Alzheimer's disease research, such studies would typically involve administering the compound to transgenic mouse models of AD and assessing its effects on cognitive function and neuropathology.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of Acacetin-7-O-β-D-galactopyranoside, as a flavonoid glycoside, may be characterized by poor oral bioavailability. It is likely metabolized by gut microbiota. The galactopyranoside moiety may enhance solubility compared to the aglycone.
|
| Toxicity/Toxicokinetics |
Preclinical toxicity data for Acacetin-7-O-β-D-galactopyranoside are limited. As a naturally occurring flavonoid, it is generally considered to have low toxicity. Comprehensive toxicological studies would be required for therapeutic development.
|
| References | |
| Additional Infomation |
Rosacrificein-7-O-β-D-galactopyranoside is a glycosyloxyflavonoid, a 7-O-β-D-galactopyranose derivative of rosacrificein. It was isolated from the inflorescence of chrysanthemum (Chrysanthemum morifolium) and has been found to possess significant anti-HIV activity. It is both a metabolite and an anti-HIV drug. It is a glycosyloxyflavonoid, a monohydroxyflavonoid, a monomethoxyflavonoid, and a β-D-galactopyranoside. Its function is related to 5,7-dihydroxy-4'-methoxyflavonoid. Rosacrificein-7-O-β-D-galactopyranoside has also been reported to be present in Chrysanthemum indicum, with relevant data available.
Acacetin-7-O-β-D-galactopyranoside is a research compound with potential applications in Alzheimer's disease research. It is a flavonoid that inhibits AChE activity and is extracted from Chrysanthemum morifolium. It is not approved for clinical use. |
| Molecular Formula |
C22H22O10
|
|---|---|
| Molecular Weight |
446.40
|
| Exact Mass |
446.121
|
| CAS # |
80443-15-8
|
| PubChem CID |
5480899
|
| Appearance |
White to off-white solid powder
|
| LogP |
0.352
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
10
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
32
|
| Complexity |
690
|
| Defined Atom Stereocenter Count |
5
|
| SMILES |
COC1=CC=C(C=C1)C2=CC(=O)C3=C(C=C(C=C3O2)O[C@H]4[C@@H]([C@H]([C@H]([C@H](O4)CO)O)O)O)O
|
| InChi Key |
NLZCOTZRUWYPTP-WHCFWRGISA-N
|
| InChi Code |
InChI=1S/C22H22O10/c1-29-11-4-2-10(3-5-11)15-8-14(25)18-13(24)6-12(7-16(18)31-15)30-22-21(28)20(27)19(26)17(9-23)32-22/h2-8,17,19-24,26-28H,9H2,1H3/t17-,19+,20+,21-,22-/m1/s1
|
| Chemical Name |
5-hydroxy-2-(4-methoxyphenyl)-7-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-4-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2401 mL | 11.2007 mL | 22.4014 mL | |
| 5 mM | 0.4480 mL | 2.2401 mL | 4.4803 mL | |
| 10 mM | 0.2240 mL | 1.1201 mL | 2.2401 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
